This is a snippet of the transcript, sign up to read more.
With that, we saw reductions in the length of stay for the respiratory populations; we were able to reduce it by about a day, because we could still provide oxygen support at home, with this continuous monitoring. It made our clinicians feel as if the efficacy and the quality of the technology was sufficient. With further partnerships with paramedics, we were able to deliver home interventions for some of those lower acuity exacerbations, rather than having patients come back to the emergency. That was one of the beauties with the Masimo technology.
This is a snippet of the transcript, sign up to read more.
We also reduced our readmission rate by 30% to 40%, during that time, with that technology. We had satisfaction rates in the 90% from our patient surveys. Our NPS score, for our end users, was above 70. Overall, I would say, it was a really good experience with them.
This is a snippet of the transcript, sign up to read more.
But also researched the interoperability of the data to get into our systems. That is something that they built, downstream, but it was not available when we first launched. That was one of the challenges with the system.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research